SecBot SecBot
PRESS-RELEASE ·Filed May 8, 2026

ARTV

Artiva Biotherapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The clinical catalyst (FDA alignment on Phase 3 design and strong efficacy data) dominates the EPS miss. Watch for EULAR 2026 presentations (June) and Phase 3 trial initiation in H2 2026. The cash runway into Q2 2027 provides a sufficient buffer for the registrational trial. Any safety or efficacy readout from the broader autoimmune dataset could further re-rate the stock.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.89
T+0 close · May 8, 2026 · via day close
Latest settled
+1.65%
T+60 · $11.07
Vs SPY
−3.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $10.89entry
  2. T+1 · 6mo ago −2.66%α −2.89% · $10.60
  3. T+5 · 6mo ago −1.93%α −3.39% · $10.68
  4. T+20 · 5mo ago −37.10%α −37.12% · $6.85
  5. T+60 · 3mo ago +1.65%α −3.19% · $11.07
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Artiva reported Q1 2026 GAAP EPS of -$0.95, missing the Street consensus of -$0.84 by 13.1%, while revenue remained $0. The net loss widened to $23.5M from $20.3M a year ago. However, the stock is likely to move on the positive clinical catalyst: FDA alignment on a single Phase 3 registrational trial for AlloNK in refractory RA, with 71% ACR50 response at six months in initial data, supporting a potential path to market.

Key Financial Metrics

EPS
−$0.95
est −$0.84 · -13.1%
Revenue
$0.00
est $0.00
Rating
strong miss

Key Facts

  • Q1 2026 GAAP EPS -$0.95 vs consensus -$0.84 (13.1% miss)
  • Net loss $23.5M vs $20.3M YoY, driven by higher R&D spend ($19.3M vs $17.1M)
  • Cash runway into Q2 2027 with $86.8M in cash and investments
  • FDA alignment on single Phase 3 registrational trial for AlloNK in refractory RA; trial initiation H2 2026
  • 71% ACR50 response at six months in refractory RA patients from Phase 2a basket trial
  • No CRS, ICANS, or treatment discontinuations reported; outpatient administration profile
  • Multiple abstracts accepted at EULAR 2026, including a late-breaking oral presentation

Financial Impact

EPS miss of $0.11 vs consensus; net loss increased $3.2M YoY; cash burn rate ~$7.8M/month

epsnet losscash

Risk Factors

  • Phase 3 trial may fail to replicate Phase 2a efficacy results
  • FDA minutes from alignment meeting could differ from Artiva's interpretation
  • Cash burn may require dilutive financing before Q2 2027 if trial costs exceed expectations
  • Competition from CAR-T therapies in autoimmune indications

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3290961

Track record

33 reports on ARTV

Performance horizon

11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
  2. Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
  3. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
  4. Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
  5. Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
  6. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  7. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  10. Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
Showing 10 of 33

US Market Status

Market Closed · Opens in 8h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026